

KELSO EQUITY PARTNERS V L P  
Form 4  
November 14, 2005

**FORM 4**

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
KELSO EQUITY PARTNERS V L P

2. Issuer Name and Ticker or Trading Symbol  
ENDO PHARMACEUTICALS HOLDINGS INC [ENDP]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
320 PARK AVENUE  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
11/11/2005

\_\_\_\_ Director  
\_\_\_\_ Officer (give title below)  
 10% Owner  
\_\_\_\_ Other (specify below)

NEW YORK, NY 10022

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3)                        | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |            |   |  |
|--|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|------------|---|--|
|  |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price                             |            |   |  |
| Common Stock, par value \$.01 per share <sup>(1)</sup> | 11/11/2005                           |  | X                              |   | 1,315   | D  | \$ 2.42                           | 17,712,553 | I | By Endo Pharma LLC <sup>(2)</sup> <sup>(3)</sup> |
| Common Stock, par value \$.01 per share <sup>(1)</sup> | 11/11/2005                           |  | X                              |   | 8,047   | D  | \$ 2.42                           | 17,704,506 | I | By Endo Pharma LLC <sup>(2)</sup> <sup>(3)</sup> |
| Common Stock, par value \$.01 per share <sup>(1)</sup> | 11/11/2005                           |  | X                              |   | 5,749   | D  | \$ 2.42                           | 17,698,757 | I | By Endo Pharma LLC <sup>(2)</sup> <sup>(3)</sup> |

Edgar Filing: KELSO EQUITY PARTNERS V L P - Form 4

|  |            |   |        |   |         |            |   |  |
|--|------------|---|--------|---|---------|------------|---|--|
| Common Stock, par value \$.01 per share <sup>(1)</sup> | 11/11/2005 | X | 12,098 | D | \$ 2.42 | 17,686,659 | I | By Endo Pharma LLC <sup>(2)</sup> <sup>(3)</sup> |
| Common Stock, par value \$.01 per share <sup>(1)</sup> | 11/11/2005 | X | 1,016  | D | \$ 2.42 | 17,685,643 | I | By Endo Pharma LLC <sup>(2)</sup> <sup>(3)</sup> |
| Common Stock, par value \$.01 per share <sup>(1)</sup> | 11/11/2005 | X | 2,861  | D | \$ 3    | 17,682,782 | I | By Endo Pharma LLC <sup>(2)</sup> <sup>(3)</sup> |
| Common Stock, par value \$.01 per share <sup>(1)</sup> | 11/11/2005 | X | 2,129  | D | \$ 3    | 17,680,653 | I | By Endo Pharma LLC <sup>(2)</sup> <sup>(3)</sup> |
| Common Stock, par value \$.01 per share <sup>(1)</sup> | 11/11/2005 | X | 7,126  | D | \$ 3    | 17,673,526 | I | By Endo Pharma LLC <sup>(2)</sup> <sup>(3)</sup> |
| Common Stock, par value \$.01 per share <sup>(1)</sup> | 11/11/2005 | X | 6,315  | D | \$ 3.42 | 17,667,212 | I | By Endo Pharma LLC <sup>(2)</sup> <sup>(3)</sup> |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|----------------------------|
| Call Option (obligation to sell)           | \$ 2.42  | 11/11/2005                           |  | X                              | 1,315   | 10/13/2005 08/26/2007                                    | Common Stock  | 1,315                      |

|  |         |            |   |        |            |            |                 |        |
|--|---------|------------|---|--------|------------|------------|-----------------|--------|
| Call Option<br>(obligation<br>to sell) | \$ 2.42 | 11/11/2005 | X | 8,047  | 10/13/2005 | 08/26/2007 | Common<br>Stock | 8,047  |
| Call Option<br>(obligation<br>to sell) | \$ 2.42 | 11/11/2005 | X | 5,749  | 10/13/2005 | 08/26/2007 | Common<br>Stock | 5,749  |
| Call Option<br>(obligation<br>to sell) | \$ 2.42 | 11/11/2005 | X | 12,098 | 10/13/2005 | 08/26/2007 | Common<br>Stock | 12,098 |
| Call Option<br>(obligation<br>to sell) | \$ 2.42 | 11/11/2005 | X | 1,016  | 10/13/2005 | 08/26/2007 | Common<br>Stock | 1,016  |
| Call Option<br>(obligation<br>to sell) | \$ 3    | 11/11/2005 | X | 2,861  | 10/13/2005 | 08/26/2007 | Common<br>Stock | 2,861  |
| Call Option<br>(obligation<br>to sell) | \$ 3    | 11/11/2005 | X | 2,129  | 10/13/2005 | 08/26/2007 | Common<br>Stock | 2,129  |
| Call Option<br>(obligation<br>to sell) | \$ 3    | 11/11/2005 | X | 7,126  | 10/13/2005 | 08/26/2007 | Common<br>Stock | 7,126  |
| Call Option<br>(obligation<br>to sell) | \$ 3.42 | 11/11/2005 | X | 6,315  | 10/13/2005 | 08/26/2007 | Common<br>Stock | 6,315  |

## Reporting Owners

| Reporting Owner Name / Address                                       | Relationships |           |         |       |
|--|---------------|-----------|---------|-------|
|  | Director      | 10% Owner | Officer | Other |
| KELSO EQUITY PARTNERS V L P<br>320 PARK AVENUE<br>NEW YORK, NY 10022 |               | X         |         |       |

## Signatures

James J.  
Connors II

11/14/2005

\_\_Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Kelso Equity Partners V, L.P. (KEP V") is the designated filer.  
  
KEP V may be deemed to share beneficial ownership of shares of Common Stock owned of record by Endo Pharma LLC by virtue of its status as a member of Endo Pharma LLC. KEP V shares investment and voting power along with the other members of Endo Pharma LLC with respect to securities owned by Endo Pharma LLC, but disclaims beneficial ownership of such securities except to the extent of its pecuniary interest.
  - (2) Each individual reporting person may be deemed to share beneficial ownership of shares of Common Stock owned of record by KEP V, by virtue of his status as a general partner of the general partner of KEP V, and each individual shares investment and voting power along with the other general partners of KEP V, but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest.
  - (3)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.